## Antibiotic Selection in Impetigo Management **Key Point:** Penicillin V is **NOT** the preferred choice for empiric impetigo treatment because it has **poor coverage of MRSA and methicillin-susceptible S. aureus (MSSA)**. Penicillin V is only appropriate if *Streptococcus pyogenes* is confirmed as the sole pathogen — which is rare in modern impetigo. ### Correct Management Principles | Scenario | First-Line Treatment | Rationale | |----------|----------------------|-----------| | **Localized (<2% BSA)** | Topical mupirocin | Avoids systemic exposure; high local concentration | | **Extensive (>2% BSA) or systemic signs** | Oral cephalexin or amoxicillin-clavulanate | Covers MSSA and *S. pyogenes*; cephalosporin preferred if MRSA suspected | | **MRSA confirmed** | Clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) | Penicillins and cephalosporins are ineffective | | **Penicillin V** | ~~Impetigo~~ | Only for confirmed *S. pyogenes* alone (rare) | ### Why Option 3 Is Wrong **High-Yield:** Penicillin V has **no activity against Staphylococcus aureus** (beta-lactamase production). Since *S. aureus* is now the dominant pathogen in impetigo (especially in India where MRSA prevalence is high), penicillin V is **not a suitable empiric agent**. Using penicillin V would result in treatment failure in the majority of cases. **Clinical Pearl:** The epidemiology of impetigo has shifted dramatically over the past two decades — *S. aureus* (including MRSA) now causes >80% of impetigo cases globally. Penicillin-based monotherapy is obsolete for this indication. **Mnemonic:** **CAMP** — Cephalosporin, Amoxicillin-clavulanate, Mupirocin (topical), Penicillin V (NOT for impetigo) [cite:KD Tripathi 8e Ch 66]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.